Assessment of vandetanib as an inhibitor of various human renal transporters: Inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance

Drug Metabolism and Disposition

Volumn 41, Issue 12, 2013, Pages 2095-2103

  Shen, Hong ^a   Yang, Zheng ^a   Zhao, Weiping ^a   Zhang, Yueping ^a   Rodrigues, A David ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CISPLATIN; CREATININE; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; UNCLASSIFIED DRUG; VANDETANIB;

ARTICLE; CREATININE CLEARANCE; CYTOTOXICITY; EMBRYO; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IC 50; KIDNEY TUBULE ABSORPTION; NEPHROTOXICITY; PRIORITY JOURNAL;

1-METHYL-4-PHENYLPYRIDINIUM; CELL LINE; CISPLATIN; CREATININE; HEK293 CELLS; HUMANS; KIDNEY; METFORMIN; ORGANIC CATION TRANSPORT PROTEINS; PIPERIDINES; QUINAZOLINES;

EID: 84888611958     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053215     Document Type: Article

References (39)

1. Blackhall FH, O'brien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ, and Thatcher N (2010) A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 5:1285-1288.
2. Ciarimboli G (2011) Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol 7:159-174.
3. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, and Schinkel AH, et al. (2010) Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176:1169-1180.
4. Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstädt H, Massmann V, Guckel D, Mathijssen RH, and Yang W, et al. (2012) Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 18:1101-1108.
5. Filipski KK, Loos WJ, Verweij J, and Sparreboom A (2008) Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14:3875-3880.
6. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, and Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86: 396-402.
7. Frampton JE (2012) Vandetanib: in medullary thyroid cancer. Drugs 72:1423-1436.
8. Franke RM, Kosloske AM, Lancaster CS, Filipski KK, Hu C, Zolk O, Mathijssen RH, and Sparreboom A (2010) Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res 16:4198-4206.
9. Go RS and Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422.
10. Han YH, Busler D, Hong Y, Tian Y, Chen C, and Rodrigues AD (2010) Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human kidney drug transporters. Drug Metab Dispos 38:1064-1071.
11. Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, Kusuhara H, and Sugiyama Y (2011) Prediction of fluoroquinolone- induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther 89:81-88.
12. Ito S, Kusuhara H, Kumagai Y, Moriyama Y, Inoue K, Kondo T, Nakayama H, Horita S, Tanabe K, and Yuasa H, et al. (2012) N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin Pharmacol Ther 92:635-641.
13. Iwata K, Aizawa K, Kamitsu S, Jingami S, Fukunaga E, Yoshida M, Yoshimura M, Hamada A, and Saito H (2012) Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol 16:843-851.
14. Jacobs C, Kalman SM, Tretton M, and Weiner MW (1980) Renal handling of cis-diamminedichloroplatinum(II). Cancer Treat Rep 64:1223-1226.
15. Khan G, Golshayan A, Elson P, Wood L, Garcia J, Bukowski R, and Rini B (2010) Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 21:1618-1622.
16. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, and Inui K (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379-386.
17. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, and Sugiyama Y (2011) Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89:837-844.
18. Langmuir PB and Yver A (2012) Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther 91:71-80.
19. Lee W and Kim RB (2004) Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 44:137-166.
20. Liu JJ, Lu J, and McKeage MJ (2012) Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. Curr Cancer Drug Targets 12:962-986.
21. Martínez-Guerrero LJ and Wright SH (2013) Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids. J Pharmacol Exp Ther 346:495-503.
22. Minematsu T and Giacomini KM (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 10:531-539.
23. Morrissey KM, Stocker SL, Wittwer MB, Xu L, and Giacomini KM (2013) Renal transporters in drug development. Annu Rev Pharmacol Toxicol 53:503-529.
24. Motohashi H, Nakao Y, Masuda S, Katsura T, Kamba T, Ogawa O, and Inui KI (2013) Precise comparison of protein localization among OCT, OAT, and MATE in human kidney. J Pharm Sci 102:3302-3308.
25. Nakamura T, Yonezawa A, Hashimoto S, Katsura T, and Inui K (2010) Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 80:1762-1767.
26. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, and Thompson J, et al. (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29:1059-1066.
27. Petrylak DP, Tangen CM, Van Veldhuizen PJ, Jr, Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, and Crawford ED (2010) Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 105:317-321.
28. Shen H, Lee FY, and Gan J (2011) Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 337:423-432.
29. Shen H, Yang Z, Mintier G, Han YH, Chen C, Balimane P, Jemal M, Zhao W, Zhang R, and Kallipatti S, et al. (2013) Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation. J Pharmacol Exp Ther 344:673-685.
30. Sprowl JA, Ness RA, and Sparreboom A (2013) Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet 28:19-27.
31. Stinchcombe TE and Socinski MA (2009) Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6:233-241.
32. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, and Endou H (2001) Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol 419:113-120.
33. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, and Inui K (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation anti-porters. Biochem Pharmacol 74:359-371.
34. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, and Inui K (2009) Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 329:185-191.
35. Urakami Y, Kimura N, Okuda M, and Inui K (2004) Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 21:976-981.
36. U.S. Department of Health and Human Services, Food and Drug AdministrationThe label approved on December 29, 2011, for platinol (cisplatin), NDA no. 018057. US FDA website, http://www.accessdata.fda.gov/drugsatfda-docs/ label/2011/018057s081lbl.pdf, (2011).
37. U.S. Department of Health and Human Services, Food and Drug AdministrationCaprelsa (vandetanib) tablets safety labeling changes October 2012. US FDA website, http://www.fda.gov/Safety/MedWatch/SafetyInformation/ ucm327503.htm, (2012).
38. Yonezawa A and Inui K (2011) Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/ toxicodynamics and pharmacogenomics. Br J Pharmacol 164:1817-1825.
39. Zolk O, Solbach TF, König J, and Fromm MF (2009) Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 379:337-348.